Rapport Therapeutics (RAPP) Competitors $12.04 +0.24 (+2.03%) As of 01:04 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock RAPP vs. ADPT, IMCR, SPRY, EWTX, SDGR, BHVN, ETNB, ANIP, JANX, and EVOShould you be buying Rapport Therapeutics stock or one of its competitors? The main competitors of Rapport Therapeutics include Adaptive Biotechnologies (ADPT), Immunocore (IMCR), ARS Pharmaceuticals (SPRY), Edgewise Therapeutics (EWTX), Schrodinger (SDGR), Biohaven (BHVN), 89BIO (ETNB), ANI Pharmaceuticals (ANIP), Janux Therapeutics (JANX), and Evotec (EVO). These companies are all part of the "pharmaceutical products" industry. Rapport Therapeutics vs. Its Competitors Adaptive Biotechnologies Immunocore ARS Pharmaceuticals Edgewise Therapeutics Schrodinger Biohaven 89BIO ANI Pharmaceuticals Janux Therapeutics Evotec Adaptive Biotechnologies (NASDAQ:ADPT) and Rapport Therapeutics (NASDAQ:RAPP) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, profitability, dividends, risk, media sentiment and earnings. Do analysts rate ADPT or RAPP? Adaptive Biotechnologies presently has a consensus target price of $10.57, suggesting a potential downside of 10.64%. Rapport Therapeutics has a consensus target price of $28.00, suggesting a potential upside of 132.56%. Given Rapport Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Rapport Therapeutics is more favorable than Adaptive Biotechnologies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Adaptive Biotechnologies 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.86Rapport Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has stronger earnings and valuation, ADPT or RAPP? Rapport Therapeutics has lower revenue, but higher earnings than Adaptive Biotechnologies. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than Rapport Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAdaptive Biotechnologies$178.96M10.04-$159.49M-$0.96-12.32Rapport TherapeuticsN/AN/A-$78.31M-$3.45-3.49 Does the media refer more to ADPT or RAPP? In the previous week, Adaptive Biotechnologies had 6 more articles in the media than Rapport Therapeutics. MarketBeat recorded 7 mentions for Adaptive Biotechnologies and 1 mentions for Rapport Therapeutics. Adaptive Biotechnologies' average media sentiment score of 0.53 beat Rapport Therapeutics' score of 0.00 indicating that Adaptive Biotechnologies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Adaptive Biotechnologies 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Rapport Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is ADPT or RAPP more profitable? Rapport Therapeutics has a net margin of 0.00% compared to Adaptive Biotechnologies' net margin of -74.84%. Rapport Therapeutics' return on equity of -25.48% beat Adaptive Biotechnologies' return on equity.Company Net Margins Return on Equity Return on Assets Adaptive Biotechnologies-74.84% -62.79% -24.55% Rapport Therapeutics N/A -25.48%-24.63% Do institutionals and insiders hold more shares of ADPT or RAPP? 99.2% of Adaptive Biotechnologies shares are held by institutional investors. 6.4% of Adaptive Biotechnologies shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. SummaryAdaptive Biotechnologies beats Rapport Therapeutics on 8 of the 14 factors compared between the two stocks. Get Rapport Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RAPP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RAPP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RAPP vs. The Competition Export to ExcelMetricRapport TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$439.46M$2.90B$5.50B$9.01BDividend YieldN/A2.64%5.39%4.11%P/E Ratio-3.4921.5027.4220.07Price / SalesN/A282.64398.50109.13Price / CashN/A41.4736.1356.90Price / Book1.447.518.015.70Net Income-$78.31M-$55.05M$3.16B$248.47M7 Day Performance1.95%3.05%2.08%2.92%1 Month Performance-1.63%5.80%4.38%5.77%1 Year Performance-48.33%6.15%35.81%21.39% Rapport Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RAPPRapport Therapeutics1.9466 of 5 stars$12.04+2.0%$28.00+132.6%-52.8%$439.46MN/A-3.49N/ANews CoverageGap UpADPTAdaptive Biotechnologies3.4705 of 5 stars$10.56+1.7%$10.57+0.1%+240.7%$1.58B$178.96M-11.00790News CoverageGap UpIMCRImmunocore2.5026 of 5 stars$31.12-0.7%$58.89+89.2%-5.9%$1.57B$310.20M-72.37320SPRYARS Pharmaceuticals2.9613 of 5 stars$16.57+4.9%$31.00+87.1%+93.4%$1.55B$89.15M-103.5690Insider TradeEWTXEdgewise Therapeutics2.6831 of 5 stars$14.18-0.8%$39.78+180.5%-29.2%$1.50BN/A-9.1560News CoverageAnalyst ForecastAnalyst RevisionGap DownSDGRSchrodinger2.8432 of 5 stars$20.35-0.5%$32.80+61.2%+3.1%$1.50B$207.54M-7.74790Analyst ForecastBHVNBiohaven2.7996 of 5 stars$14.44-0.2%$58.46+305.0%-56.8%$1.48BN/A-1.54239ETNB89BIO1.9619 of 5 stars$10.00-0.8%$26.43+164.3%+32.9%$1.47BN/A-2.9640ANIPANI Pharmaceuticals3.7493 of 5 stars$66.03+0.7%$80.13+21.3%+4.1%$1.42B$614.38M-51.99600JANXJanux Therapeutics1.8526 of 5 stars$22.88-3.1%$95.25+316.3%-38.8%$1.40B$10.59M-16.8230EVOEvotec1.6772 of 5 stars$3.81+1.3%$5.93+55.7%-12.3%$1.34B$862.40M0.004,827Positive News Related Companies and Tools Related Companies ADPT Competitors IMCR Competitors SPRY Competitors EWTX Competitors SDGR Competitors BHVN Competitors ETNB Competitors ANIP Competitors JANX Competitors EVO Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RAPP) was last updated on 7/3/2025 by MarketBeat.com Staff From Our PartnersTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredA grave, grave error.President Donald Trump made headlines last month with a staggering claim. He stated that since taking offic...Porter & Company | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rapport Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rapport Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
